Meningitis C vaccine
|WHO AWaRe||UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽|
Meningoccal C vaccine (MenC), is a meningitis vaccine that protects against Neisseria meningitidis type C. It is available either combined with Haemophilus type b vaccine or with other types of meningitis, the MenACWY vaccine. It has been shown to dramatically reduce cases of meningitis C to levels of almost none, when part of a routine vaccination schedule.
Common side effects include redness, pain and swelling at the site of injection. There may be a slight fever, feeling of not wanting to eat, a tummy upset, irritability and poor sleep.  Rarely, there may be dizziness, high fever or fainting.
The first monovalent MenC was licensed in the UK in 1999 and entered routine vaccination schedules there form November of that year. By 2001, MenC cases in the UK dropped 87% in those who received the vaccine. It continued to be used as a monovalent vaccine until 2016.
- Pollard, Andrew J.; Snape, Matthew D.; Sadarangani, Manish (2021). "22. Meningoccal vaccines". In Vesikari, Timo; Damme, Pierre Van (eds.). Pediatric Vaccines and Vaccinations: A European Textbook (Second ed.). Switzerland: Springer. pp. 253–254. ISBN 978-3-030-77172-0. Archived from the original on 2022-06-14. Retrieved 2022-06-13.
- Suryadevara, Manika (2021). "19. Meningococcus". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. pp. 235–246. ISBN 978-3-030-58416-0. Archived from the original on 2022-01-11. Retrieved 2022-06-13.
- "MenC Vaccine (Meningococcal C Vaccine)". www.ovg.ox.ac.uk. Vaccine Knowledge Projective. 15 March 2022. Archived from the original on 16 November 2021. Retrieved 13 June 2022.